1 |
Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update[J]. Circulation, 1993, 88 (2): 782-784.
|
2 |
Sun AY, Pitt GS. Long QT syndrome and seizures[J]. JACC Clin Electrophysiol, 2016, 2 (3): 277-278.
|
3 |
Mullally J, Goldenberg I, Moss AJ, et al. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations[J]. Heart Rhythm, 2013, 10 (3): 378-382.
|
4 |
Refaat MM, El Hage L, Steffensen AB, et al. Iron overload leading to torsades de pointes in β-thalassemia and long QT syndrome[J]. Card Electrophysiol Clin, 2016, 8 (1): 247-256.
|
5 |
Gessner G, Runge S, Koenen M, et al. ANK2 functionally interacts with KCNH2 aggravating long QT syndrome in a double mutation carrier[J]. Biochem Biophys Res Commun, 2019, 512 (4): 845-851.
|
6 |
Mohler PJ, Le Scouarnec S, Denjoy I, et al. Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes[J]. Circulation, 2007, 115 (4): 432-441.
|
7 |
Swayne LA, Murphy NP, Asuri S, et al. Novel variant in the ANK2 membrane-binding domain is associated with ankyrin-B syndrome and structural heart disease in a first nations population with a high rate of long QT syndrome[J]. Circ Cardiovasc Genet, 2017, 10 (1): e001537.
|
8 |
Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function[J]. Proc Natl Acad Sci U S A, 2004, 101 (24): 9137-9142.
|
9 |
Kaltman JR, Evans F, Fu YP. Re-evaluating pathogenicity of variants associated with the long QT syndrome[J]. J Cardiovasc Electrophysiol, 2018, 29 (1): 98-104.
|
10 |
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)[J]. Europace, 2011, 13 (8): 1077-1109.
|